BioSpace News Archive

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore” or the “Company”) has achieved significant milestones in completing due diligence, technical reviews and initial connectivity between its real-time data reporting platform, HealthTab™ and a leading point-of-care device

More than 4 million people in the United States are expected to have glaucoma by 2030. This serious disease is one of the leading causes of blindness, yet patients do not know that elevated eye pressure is the only treatable risk factor.

Indica Labs, a leading provider of computational pathology software and services, are pleased to announce the formal launch of an enterprise-wide, cloud-based deployment of Indica Labs’ software within the National Cancer Institute (NCI), including HALO®, HALO AI, HALO Link and HALO AP.

ALK Life Science Solutions, a business unit of ALK-Abelló, Inc. (ALK), serving the North American pharmaceutical packaging-based market for glass vials, and UPPI, LLC, the largest association of independent and university-based nuclear pharmacies serving the diagnostic imaging community in the U.S.,

Knopp Biosciences LLC announced that it entered the second year of research funded by the National Institutes of Health to utilize its Kv7 platform to discover and develop non-opioid therapies for the treatment of chronic pain.

Moderna, Inc. announced that it has regained all rights to the respiratory syncytial virus vaccine from Merck, known as MSD outside the United States and Canada, including rights to develop RSV vaccines for adult populations.

Award part of DARPA’s Nucleic Acids On-Demand World-Wide (NOW) initiative to develop a medical countermeasure manufacturing platform

IRADIMED CORPORATION announced that the Company will release its 2020 third quarter financial results before the market opens on Friday, October 30th.

Spinal Elements Holdings, Inc. (“Spinal Elements”), a CA-based spine technology company, today announced the launch of its initial public offering of 7,700,000 shares of its common stock at an anticipated initial public offering price between $13.00 and $15.00 per share pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to grant the underwriters a 30-day

--Study suggests all cancer patients could benefit from both germline and somatic testing, utility of germline testing in identifying additional treatment options for cancer patients -- [08-October-2020] SAN FRANCISCO , Oct. 8, 2020 /PRNewswire/ -- Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germlin